FDAMA In Action? ODE Shows Progress On IDE Supplements, Five-Day Notice
This article was originally published in The Gray Sheet
The Center for Devices and Radiological Health is addressing industry concerns over FDA's handling of increasing numbers of investigational device exemption supplements and use of the agency's five-day notice program for clinical trial changes
You may also be interested in...
FDA should consult with a three-person "supervisory" panel in deciding whether to narrow a proposed indication statement for 510(k) devices, Cook Group, Inc. suggests in March 4 comments to HHS Secretary Thompson's regulatory reform advisory committee
Physician studies of W.L. Gore's Helex septal occluder, used in the closure of atrial septal defects, demonstrate that the device can also close patent foramen ovale (PFO) for prophylaxis of recurrent paradoxical embolism and embolic stroke
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.